RT期刊文章SR电子T1的睡眠药物使用频率之间的联系和大脑形态学(P3.058)摩根富林明神经学神经学乔FD Lippincott Williams &威尔金斯SP P3.058 VO 88是16补充A1 Angeliki Tsapanou A1首页燕顾A1妖妇海德尔A1 Jayant Sakhardande A1 Nikolaos斯卡尔米斯A1班斯特恩年2017 UL //www.ez-admanager.com/content/88/16_Supplement/P3.058.abstract AB目的:检查睡眠药物使用频率之间的关系和大脑形态在健康老年人。背景:睡眠药物使用有关的生活质量,尤其在老年人。睡眠药物直接作用于大脑区域。因此,研究睡眠的药物使用频率之间的关系和任何大脑形态学特性至关重要。设计/方法:横断面研究的97名参与者的睡眠和大脑体积数据,所有超过65岁,无痴呆或任何主要的精神或神经疾病(中风)。参与者来自两个认知正常的个体——的研究。睡眠药物频率与以下项目的评估匹兹堡睡眠质量指数:“在过去的一个月,多长时间你吃过药(规定或“柜台”)来帮助你的睡眠。答案的范围0 - 3得分越高表明更大的频率。T-weighted MRI图像获取,区域脑容量与FreeSurfer——大脑成像软件计算。卷:总皮层、皮层下灰质总灰质,皮质白质,大脑分割,supratentorium计算每个参与者。颅内的所有大脑措施调整音量。 Age, sex, education, and body mass index were used as covariates. Linear regression models were computed, with sleep medication frequency as the predictor and each of the brain volumes as the dependent variable.Results: Higher frequency of sleep medication use was significantly associated with decreased: subcortical gray matter (β=−0.361, p=0.028), total gray matter (β= −0.347, p=0.040), as well as supratentorial (β= −0.380, p=0.031) volumes. The associations remained significant even after adjusting for depression.Conclusions: This is the first study to examine the association between frequency of sleep medication use and brain morphology in a healthy group of older adults. Metabolic effects or a possible neurotoxicity could play a role to the observed associations.Study Supported by:NIH R01AG038465-02NIH R01AG026158-07Research programs of excellence IKY/SIEMENS for Angeliki Tsapanou, Nikolao ScarmeaDisclosure: Dr. Tsapanou has nothing to disclose. Dr. Gu has nothing to disclose. Dr. Haider has nothing to disclose. Dr. Stern has received personal compensation for activities with Takeda, Axovant, and Eli Lilly and Company as an advisor and/or consultant. Dr. Stern has received license fees from Columbia. Dr. Stern has received research support from Axovant, Piramal and the California Walnut Commission. Dr. Scarmeas has nothing to disclose. Dr. Stern has received personal compensation for activities with Takeda, Axovant, and Eli Lilly and Company as an advisor and/or consultant. Dr. Stern has received license fees from Columbia. Dr. Stern has received research support from Axovant, Piramal and the California Walnut Commission.